Galera raises $11M A round; Can Novo make liraglutide into obesity blockbuster?; Infinity shoots up on blood cancer data;

 @FierceBiotech: GSK employs mobile phones to up vaccination rates in Africa. Story | Follow @FierceBiotech

@JohnCFierce: Sofinnova reaps $312M for its dedicated life sciences fund. Wished we saw more of these. News | Follow @JohnCFierce

> Galera Therapeutics has raised an $11 million Series A round for its programs on cancer and fibrosis. The round was co-led by New Enterprise Associates and Novartis Venture Fund and includes Correlation Ventures. Release

> Shares of Infinity Pharmaceuticals ($INFI) shot up after it announced positive results from an early-stage study of IPI-145 for blood cancers. Its stock jumped 21%. Story

> Reuters covers Novo Nordisk's ($NVO) plans to make the diabetes drug liraglutide into a new therapy for the seriously obese, developing a premium pricing model that has the potential to add significantly to its revenue. Story

> The Fred Hutchinson Cancer Research Center and GlaxoSmithKline ($GSK) announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy. Release

Pharma News

@FiercePharma: AbbVie shares fall in first day of 'when-issued' trading. Story | Follow @FiercePharma

> KV, Hologic reach $60 million deal on Makena. News

> J&J's Zytiga gets expanded approval that could double sales. Story

> Pernix snatches struggling Somaxon for $25M. Article

Medical Device News

 @FierceMedDev: Exact Sciences heads to the FDA with cancer diagnostic. Story | Follow @FierceMedDev

@MarkHFierce: MIT's Robert Langer is at it again--using porcupine quills as a model for next-generation medical device needles. More | Follow @MarkHFierce

 @DamianFierce: The effort to delay the medical device tax has picked up some Democratic support. Report | Follow @DamianFierce

> Japan's regulators approve Thoratec's HeartMate II pump. News

> India lures med tech manufacturing interest. Story

> Covidien's blood monitor will ship with GE's infant warmers. Item

Biotech Research News

> New molecule opens door to lymphoma combination therapy. News

> Seattle Genetics' next-gen antibody-drug conjugate tackles leukemia in the lab. Report

> Preclinical data snags GlaxoSmithKline's attention in $335M cancer immunotherapy deal. Article

> MicroRNAs could heal broken hearts. Item

Pharma Manufacturing News

> Novo selling Bangladeshi-made insulin after plant fires up. Story

> Congress investigating compounding pharmacy trade group. Item

> Endo reports oversized problem with oversized pain meds. Article

> Pharma files lawsuit against California drug disposal law. News

And Finally… Investigators at the University of Michigan and Harvard have been probing an anti-aging gene that suppresses cancer growth. Story


Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.